Seven new drugs on track for approval and recent launch will be blockbuster treatments in the next five years

A few days ago, Clarivate, a well-known organization in the industry, released the latest Drugs to Watch™ report

Data source: Reference [1]; Drawing by WuXi AppTec Content Team

Adagrasib (Mirati Therapeutics, Zai Lab)

Adagrasib is a highly specific and potent oral KRAS G12C inhibitor that has been granted Breakthrough Therapy Designation by the U.

Outside of lung cancer, Clarivate's report indicates that adagrasib is expected to be the first treatment for patients with colorectal cancer with the KRAS G12C mutation

Faricimab (Roche, Chugai Pharmaceutical)

Faricimab is a bispecific antibody that is expected to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

Clarivate's report notes that the therapy may be more convenient because it is administered less frequently than standard therapy

Lecanemab (Eisai, Biogen)

Donanemab (Lilly)

Since the Alzheimer's disease treatment Aduhelm (aducanumab) was approved last year, several companies in the industry are accelerating their projects for Alzheimer's disease treatments

In a phase 2b clinical trial, researchers included 856 patients with mild cognitive impairment (MCI) due to AD or mild AD who confirmed the presence of amyloid pathology

Similarly, donanemab, a monoclonal antibody targeting amyloid beta, developed by Eli Lilly, has also met its primary endpoint in a phase 2 clinical trial, slowing clinical progression by 32% in patients with early-stage Alzheimer's disease

Clarivate's report points to the promise of differentiated clinical profiles for the two Alzheimer's treatments, and Phase 3 results expected by the end of this year are likely to further strengthen these data

Tezepelumab (Amgen, AstraZeneca)

Tezepelumab has been approved in late 2021 as add-on maintenance therapy for the treatment of severe asthma in children and adults over 12 years of age

Clarivate's report mentions that this is a "first-in-class" biological therapy for this patient group, and is expected to be the first-line therapy for severe low TH2 asthma (TH2-low asthma) and may also become the first-line therapy for high TH2 asthma (TH2- A new treatment option for high asthma

Tirzepatide (Lilly)

Tirzepatide is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin-stimulating polypeptide) receptors and is expected to treat diabetes

According to Clarivate's report, the therapy is expected to bring greater benefits to patients by controlling weight and blood sugar in a growing patient population, and has the potential to reduce complications associated with type 2 diabetes

Vutrisiran (Alnylam)

Vutrisiran is a subcutaneously administered RNAi therapeutic for the treatment of transthyretin-mediated (ATTR) amyloidosis, including hATTR and wild-type ATTR (wtATTR) amyloidosis

The Clarivate report noted that the therapy is generally safe and effective, and that improved delivery could improve patients' quality of life and address unmet medical needs

In addition to these seven therapies that are expected to become blockbusters in five years, this Clarivate report also analyzes current COVID-19 vaccines and therapies, cell and gene therapy, CRISPR, AI drug discovery, RNA therapy, and cancer targeting therapy,

References:

[1] Drugs to Watch in 2022, Retrieved January 12, 2022, from https://clarivate.
com/drugs-to-watch/

[2] Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report, Retrieved January 12, 2022, from https://clarivate.
com/news/clarivate-identifies-seven-potential-blockbuster-drugs-in-annual-drugs -to-watch-report/

[3] 7 blockbusters: Analysts spotlight 2022's crop of drugs most likely to win top marketing status — 2 drugs dominate, Retrieved January 12, 2022, from https://endpts.
com/7-potential-blockbusters-analysts-spotlight-the -mostly-likely-drugs-to-hit-the-1b-mark-within-5-years/